Download Free Medical Colon Cancer PowerPoint Presentation

Colon Cancer PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : colon cancer. FACTORS AFFECTING PDL1 and PD1 EXPRESSION

Tags : colon cancer, immunotherapy, PD-L1, B7-H1

Published on : Oct 13, 2020 | Views : 1356 | Downloads : 6

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Factors affecting PDL1 & PD1 expression Professor: Dr.Zuhair Mohammad Hassan
Slide 2-

Headlines Introduction Signaling Mechanisms regulating PD-L1 expression The Effect of cytokines on the PD1 & PDL1 expression The effect of some microRnas on the PD1 & PDL1 expression Immunotherapy
Slide 3-

Introduction PD-L1, also known as B7-H1, is a type I transmembrane protein, which is expressed in different kinds of tumor cell . PD-L1 can bind to PD-1, which leads to the suppression of lymphocyte activation and apoptosis of lymphocytes PD-L1 can regulate tumor microenvironment or tumor related immune response through suppressing T cell or NK cell mediated immune response. PD-L1expression is regulated by various cytokines, such as IFNg , TGF B, and various microRNAs
Slide 4-

PD-L1/PD-1 signaling pathway
Slide 5-

Mechanisms regulating PD-L1 expression A tumor can be positive or negative for surface PD-L1 expression through several biological processes, thereby having different clinical significance. These can be categorized as: genetic mechanisms that lead to constitutive PD-L1 expression induced PD-L1 expression by the presence of T cells absence of T cells leading to no reactive PD-L1 expression
Slide 6-

Constitutive PD-L1 expression PD-L1 has been reported to be constitutively expressed through the dysregulation of several oncogenic pathways, including : genetic amplification of chromosome 9 PTEN deletions or PI3K/AKT mutations EGFR mutations MYC overexpression
Slide 7-

Inducible PD-L1 expression The interferon-inducible expression of PD-L1 is more common than the constitutive expression in most cancer histologies The PD-L1 adaptive expression is a consequence of the presence of tumor antigen–specific T cells that recognized the cancer cells leading to the production of interferon-γ. The physiological induction of PD-L1 by interferon-γ leads to evasion of a T cell response, termed adaptive immune resistance
Slide 8-

Dual Faces of IFNg in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro and Antitumor Immunity IFNg elicits potent antitumor immunity by inducing Th1 polarization, CTL activation, and dendritic cell tumoricidal activity. However, there are signiﬁcant discrepancies in our understanding of the role of IFNg as an antitumor cytokine
Slide 9-

Role of IFNg in physiologic and tumor immunity IFNg plays a pivotal role in systemic and local immunity and is involved in almost all inﬂammatory responses IFNg is a key cytokine in the polarization of Th1 cells. IFNg secretion by NK cells and dendritic cells (DC) causes the local production of IL12 and there by induces aTh1 response IFNg is essential to the induction of the proliferation of CTL precursors and their differentiation into CTLs
Slide 10-

Conﬂicting Data from Basic and Clinical Research on IFNg Treatment Negative effects of IFNg on tumor inhibition: (SOCS1)-deﬁcient mice spontaneously developed colorectal carcinomas in an IFNg-dependent manner IFNg has been demonstrated to promote papilloma development Mouse mammary adenocarcinomas transfected with the murine IFNg gene give rise to progressive tumors
Slide 11-

We propose IFNg-induced programmed cell death 1 ligand 1 (PD-L1) expression as a novel mechanism by which IFNg impairs tumor immunity When tumor cells encounter CTLs in the local environment, they detect them via the high concentration of IFNg secreted from CTLs, which induces PD-L1 expression in preparation for an immune attack.
Slide 12-

Use of an ovarian cancer model to investigate the mechanism underlying PD-L1 expression in most of the human and mouse ovarian cancer cells, PD-L1expression was strongly induced by IFNg. Other cytokines, including IL2, IL6, and TGFb, did not induce PD-L1 expression in vitro. we cocultured mouse ovarian cancer cells with mouse CD8+ T cells recovered from the ascites of cancer-inoculated mice or with the supernatants of the ascites ﬂuid. Notably, PD-L1 expression by the cancer cells was strongly induced by coculture with CD8+ T cells but not with the ascetic supernatant, which suggests that direct contact with T cells is necessary for the induction of PD-L1. It is possible that paracrine exposure to the IFNg secreted by T cells induces PD-L1.
Slide 13-

Use of an ovarian cancer model to investigate the mechanism underlying PD-L1 expression To test this hypothesis, the IFNg receptor was knocked down in ovarian cancer cells using shRNA, and mice were intra-abdominally inoculated with these cells. The expression of PD-L1 by the IFNg receptor–depleted cancer cells was reduced,which indicates that IFNg also mediated PD-L1 expression invivo Consequently , CD8+T-cell inﬁltration into the tumor site was signiﬁcantly increased ,and the survival of the mice was signiﬁcantly improved compared with the mice inoculated with control mouse ovarian cancer cells
Slide 14-

ppt slide no 14 content not found
Slide 15-

transforming growth factor-β (TGF-β) Because increased TGF-β 1production is a hallmark of most TME, we chose to further explore its role in PD-1 expression To assess the effects of cytokines known to alter T cell development, function, and/or proliferation on PD-1 expression: CD3+ T cells isolated from healthy donor peripheral blood mononuclear cells (PBMC) activated them with αCD3/αCD28-conjugated beads in the presence of one of 16 cytokines across a range of concentrations The cells were labeled with CFSE to monitor cellular proliferation
Slide 16-

Results αCD3/ αCD28 induces higher PD-1 expression compared to resting CD8+ and CD4+ T cells, confirming TCR and co-stimulation dependent PD-1 expression While most of the cytokines tested had no effect or only a modest effect on PD-1 expression upon T cell activation, major enhancement of PD-1 expression was observed with TGF-β1
Slide 17-

TGF-β1 did not have any effects on cellular proliferation as measured by CFSE dilution suggesting that enhanced PD-1 expression is not simply due to altered cellular proliferation
Slide 18-

Factors affecting the effect of the TGF-β To test whether TGFβ1-mediated enhancement of PD-1 expression depends on the basal level of PD-1 expression, we isolated naïve T cells and memory T cells from healthy donors The cells were activated with αCD3/αCD28-conjugated beads with TGFβ1 the effect was more pronounced on naïve T cells than on memory T cells for both CD4 and CD8 subsets
Slide 19-

In the absence of αCD3/αCD28, TGF-β1 does not affect the basal levels of PD-1 expression on either naïve or memory T cell subsets. This suggests that TGF-β1 enhancement of PD-1 expression is dependent on T cell activation (TGF-β1) directly enhances antigen-induced PD-1 expression through Smad3 -dependent, Smad2 -independent transcriptional activation in T cells in vitro and in TIL in vivo The PD-1hi subset seen in CD8+ TIL is absent in Smad3 -deficient tumorspecific CD8+ TIL, resulting in enhanced cytokine production by TIL and in draining lymph nodes and of anti-tumor activity
Slide 20-

TGF-β receptor I (TGF-βRI) kinase activity is critical for TGF-β-dependent enhancement of PD-1 expression To address the role of TGF-β1 receptor signaling , they used neutralizing antibody (nAb) : TGFB inhibitor TGF-βRI kinase inhibitor (SB431542)
Slide 21-

Both TGF-β1 nAb and SB431542 decreased TGF-β1-dependent PD-1 expression , although SB431542 was more effective than TGF-β1 nAb
Slide 22-

NFAT Given the critical role of nuclear factor of activated T cell (NFATc1) during TCR dependent PD-1 induction we tested whether TGF-β1-dependent PD-1 expression requires NFATc1 by treating cells with cyclosporine A (CsA) We found that CsA completely abrogated not only TCR-dependent but also TGF-β1 enhanced PD-1 expression suggesting that TGF-β1 requires TCR-induced NFATc1 activity to enhance the PD-1 expression
Slide 23-

The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint With the development of whole genome sequencing technologies, microRNAs have gained more attention as an important new layer of molecular regulation. Recent studies have revealed that altered expression of microRNAs play a pivotal role in immune checkpoint and various cellular processes in cancer
Slide 24-

. Current Knowledge on MicroRNAs Involved in PD-1/PD-L1 Regulation microRNA effect on PD1 & PDL1 expression Directly : Some microRNAs have been found to directly target the 3`-UTR of PD-1 or PD-L1 mRNA Indirectly : Some microRNAs may regulate PD-1/PD-L1 indirectly via signaling molecules such as PTEN, STAT , and so on
Slide 25-

MicroRNAs That Regulate PD-1/PD-L1 Directly MicroRNAs Regulating PD-1 Expression MiR-28 MiR-138 MiR-4717 Reduction of PD1 expression regulating T cell exhaustion Inhibition of PD1 expression Reduction of PD1 expression
Slide 26-

MicroRNAs Regulating PD-L1 Expression PD-L1 mRNA dropped in malignant pleural mesothelioma cell line (VMC23) after transfection with miR-15a, miR-15b or miR-16 mimic in 44 acute myeloid leukemia (AML) samples , Over-expression of miR-34a in HL-60 and Kasumi-1 cells reduced the expression of PD-L1 To examine the effect of miR-138 on endogenous PD-L1 expression, two cell lines with low miR-138 expression, colorectal cancer cell lines (HCT116 and SW620), were transfected with miR-138 mimics. PD-L1 protein levels were decreas miR-15a & miR-16 miR-138 miR-34a
Slide 27-

Potential PD-1/PD-L1 Regulatory microRNAs Some emicroRNAs that may affect PD-1/PD-L1expression via regulation of the related signaling pathways such as IFN-γ / IFNGR / JAK / STAT / PI3K / AKT / MEK / ERK and so on. MicroRNAs Regulating IFN-γ Expression : miR-181a MicroRNAs Regulating IFNGR Expression: miR-378 MicroRNAs Regulating STAT1 Expression: MiR-150 , MiR-223 MicroRNAs Regulating PTEN Expression : MiR-10a / MiR-19a/ MiR-19b
Slide 28-

ppt slide no 28 content not found
Slide 29-

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy Several cancers are highly refractory to conventional chemotherapy Check point antibody inhibitors, such as anti-PD-1/PD-L1, are a novel class of inhibitors that function as a tumor suppressing factor via modulation of immune cell-tumor cell interaction These checkpoint blockers are rapidly becoming a highly promising cancer therapeutic approach that yields remarkable antitumor responses with limited side effects
Slide 30-

MAbs can: being able to shrink solid tumors suppress advanced tumors and metastasis and overall improve patient survival
Slide 31-

PD-1/PD-L1 INHIBITION AND THEIR INHIBITORS
Slide 32-

PD-1 INHIBITORS APPROVED BY FDA Nivolumab : In the Treatment of: Pembrolizumab: in the treatment of : Head and Neck Squamous Cell Carcinoma (HNSCC) Melanoma Renal Cell Carcinoma NSCLC HNSCC
Slide 33-

PD-L1 INHIBITORS APPROVED BY FDA Atezolizumab In the Treatment of : NSCLC Urothelial Carcinoma
Slide 34-

PD-1 INHIBITORS FOR COMBINATION THERAPY Considering the safety and better clinical activity of monotherapy the ﬁeld is moving toward the direction of discovering novel combination therapies Various anti-cancer agents including other check point inhibitors, kinase inhibitors, chemotherapeutics, and targeting agents are used in combination with PD-1 antibody inhibitors
Slide 35-

Combination of PD-1 and Other Checkpoint Inhibitors ipilimumab as an anti-CTLA4 Ab , has shown durable anti-tumor activities and prolonged survival in participants with advanced melanoma. ipilimumab, perhaps because of its function in the priming phase of the immune response, it also appears to activate immunity against many types of normal tissues causing severe immune-related adverse events (irAEs) in a substantial minority of patients The combination of ipilimumab and Nivolumab are undergoing human trials for advance melanoma, and nonsmall cell lung carcinoma
Slide 36-

Combination of PD-1 and Kinases Inhibitors Mitogen-activated protein kinase (MAPK) is an eﬀective regulator of BRAF mutation, which is responsible for the metastasis of cutaneous melanoma In the clinic, BRAF inhibition has improved metastasis of melanoma The mutation of BRAF has also increased the expression of the PD-1 and PDL-1 molecule and induces potential drug resistance with the involvement of tumor stromal cells The combination of PD1 immunotherapy with a BRAF inhibitor resulted in synergistic anti-tumor response and prominent tumor growth inhibition
Slide 37-

There is proof that VEGF suppresses dendritic cell (DC) functions; thus, restoring DC and T-cell activity could improve immune response and anti-tumor activity A phase I clinical study of VEGF inhibitors (bevacizumab) combined with Nivolumab is ongoing for stage III NSCLC patients and unresectable stage III or IV melanoma
Slide 38-

Combination of PD-1 inhibitor and Chemotherapeutics PD-1 inhibitors are being treated in combination with antineoplastic agents, such as cisplatin, to achieve a longlasting synergistic anti-cancer eﬀect For example: a phase 3 study is recruiting gastric adenocarcinoma patients for combination of pembrolizumab either with cisplatin or 5-ﬂuorouracil
Slide 39-

Recent trends in cancer treatment are moving toward combination immunotherapy, but its success depends on addressing the challenges of choosing the right drug combination, optimizing the dose and schedule of the combination regimen, and managing toxicities and side eﬀects.
Slide 40-

ppt slide no 40 content not found